Marker Therapeutics, Inc.

A major leap forward in cell therapy

The Company

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results

Marker Therapeutics today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.

Read more

Marker Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, November 9, 2020

Marker Therapeutics, Inc. today announced that it will host a conference call and webcast on Monday, November 9, 2020 at 5:00 p.m. Eastern Time to review its third quarter 2020 financial and operating results and provide a corporate update.

Read more